Mymetics Reports Successful Preclinical Study Results with COPVirosomes as Second-Generation Allergy Immunotherapy
- Second-generation Allergen Immunotherapy with COP-virosomes, based on Anergis Contiguous Overlapping Peptides (COP) linked to Mymetics virosomes were tested by Stallergenes Greer in a therapeutic model of birch pollen allergy.
- The results showed that a treatment with COP-virosomes was able to cure allergic asthma in birch pollen sensitized mice.
- The COP-virosomes were significantly superior to the COP or the virosome alone, confirming the synergy between COP and virosomes to foster an improved second generation AIT treatment.
- The results of the study will soon be published.
EPALINGES, Switzerland, May 28, 2020 Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines and immunotherapies against life threatening and life disabling diseases, announced today that Stallergenes Greer, a worldwide leader in allergen immunotherapy (AIT) and Anergis, a leader in ultra-fast AIT research and development, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.
In 2018, Anergis and Mymetics reported that the COP-Virosomes were able to elicit a strong boost in TH1 antibody response without any IgE response, unlike the first generation of COPs associated with aluminum hydroxide.
In this new study conducted by Stallergenes Greer, COP-Virosomes, and COP and virosomes alone were compared to a placebo group in an in-house therapeutic model of birch pollen allergy. Recombinant Bet v 1 alone (the major allergen of birch pollen) and birch extract were also used as controls in this setting.
COP-virosomes were the only synthetic therapy able to fully reverse asthma symptoms as well as lung inflammation (i.e. significant reduction in eeosinophils in bronchial fluids). Pro-allergic immune responses also decreased with COP-virosome therapy with a significant decrease of the IL-4, a Th2 cytokine. The results of the study will soon be published.
"This new data confirms that COP-virosomes are likely to be more efficacious clinically than a recombinant allergen or than our first generation COP allergy vaccines which did not include the Mymetics virosomes. COP-virosomes may thus represent a breakthrough AIT treatment of the future", said Vincent Charlon, CEO of Anergis.
"This thorough study by Stallergenes Greer is a second confirmation of the potential for the COP-virosomes allergy therapy and we now look forward to turn this into a business opportunity and developing a safe and ultra fast immunotherapy against birch pollen allergy with Anergis", said Ronald Kempers, CEO of Mymetics.
Read the full Press Release